258 related articles for article (PubMed ID: 3079613)
1. Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen.
Youle RJ; Uckun FM; Vallera DA; Colombatti M
J Immunol; 1986 Jan; 136(1):93-8. PubMed ID: 3079613
[TBL] [Abstract][Full Text] [Related]
2. Antigenic modulation by anti-CD5 immunotoxins.
Manske JM; Buchsbaum DJ; Azemove SM; Hanna DE; Vallera DA
J Immunol; 1986 Jun; 136(12):4721-8. PubMed ID: 3086441
[TBL] [Abstract][Full Text] [Related]
3. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
[TBL] [Abstract][Full Text] [Related]
4. Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65,000 protein immunotoxins.
Stong RC; Youle RJ; Vallera DA
Cancer Res; 1984 Jul; 44(7):3000-6. PubMed ID: 6372999
[TBL] [Abstract][Full Text] [Related]
5. Anti-T cell monoclonal antibodies conjugated to ricin as potential reagents for human GVHD prophylaxis: effect on the generation of cytotoxic T cells in both peripheral blood and bone marrow.
Quinones RR; Youle RJ; Kersey JH; Zanjani ED; Azemove SM; Soderling CC; Lebien TW; Beverley PC; Neville DM; Vallera DA
J Immunol; 1984 Feb; 132(2):678-83. PubMed ID: 6606676
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
7. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
Seon BK
Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488
[TBL] [Abstract][Full Text] [Related]
8. Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia.
Uckun FM; Myers DE; Ledbetter JA; Swaim SE; Gajl-Peczalska KJ; Vallera DA
J Immunol; 1988 Mar; 140(6):2103-11. PubMed ID: 3126241
[TBL] [Abstract][Full Text] [Related]
9. Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation.
Ramakrishnan S; Uckun FM; Houston LL
J Immunol; 1985 Nov; 135(5):3616-22. PubMed ID: 3900212
[TBL] [Abstract][Full Text] [Related]
10. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease.
Fauser AA; Shustik C; Langleben A; Laurent G; Kanz L; Spurll GM; Price G; Ahlgren PD; Cooper BA
Clin Invest Med; 1988 Feb; 11(1):40-6. PubMed ID: 3284672
[TBL] [Abstract][Full Text] [Related]
11. Investigation of early T cell activation: analysis of the effect of specific antigen, interleukin 2 and monoclonal antibodies on intracellular free calcium concentration.
O'Flynn K; Zanders ED; Lamb JR; Beverley PC; Wallace DL; Tatham PE; Tax WJ; Linch DC
Eur J Immunol; 1985 Jan; 15(1):7-11. PubMed ID: 2578401
[TBL] [Abstract][Full Text] [Related]
12. Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin.
Kernan NA; Knowles RW; Burns MJ; Broxmeyer HE; Lu L; Lee HM; Kawahata RT; Scannon PJ; Dupont B
J Immunol; 1984 Jul; 133(1):137-46. PubMed ID: 6609971
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
Weil-Hillman G; Runge W; Jansen FK; Vallera DA
Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
[TBL] [Abstract][Full Text] [Related]
14. A flexible peptide spacer increases the efficacy of holoricin anti-T cell immunotoxins.
Marsh JW; Neville DM
J Immunol; 1988 May; 140(10):3674-8. PubMed ID: 2896212
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials.
Woo JH; Lee YJ; Neville DM; Frankel AE
Methods Mol Biol; 2010; 651():157-75. PubMed ID: 20686966
[TBL] [Abstract][Full Text] [Related]
16. A C terminus cysteine of diphtheria toxin B chain involved in immunotoxin cell penetration and cytotoxicity.
Dell'Arciprete L; Colombatti M; Rappuoli R; Tridente G
J Immunol; 1988 Apr; 140(7):2466-71. PubMed ID: 2965187
[TBL] [Abstract][Full Text] [Related]
17. Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation.
Stong RC; Uckun F; Youle RJ; Kersey JH; Vallera DA
Blood; 1985 Sep; 66(3):627-35. PubMed ID: 3896347
[TBL] [Abstract][Full Text] [Related]
18. Selective killing of human T-lymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin.
Krönke M; Schlick E; Waldmann TA; Vitetta ES; Greene WC
Cancer Res; 1986 Jul; 46(7):3295-8. PubMed ID: 3011246
[TBL] [Abstract][Full Text] [Related]
19. Properties of immunotoxins against a glycolipid antigen associated with Burkitt's lymphoma.
Wiels J; Junqua S; Dujardin P; Le Pecq JB; Tursz T
Cancer Res; 1984 Jan; 44(1):129-33. PubMed ID: 6690030
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of protein synthesis inactivation in human T-lymphocytes by selective monoclonal antibody-ricin conjugates.
Leonard JE; Wang QC; Kaplan NO; Royston I
Cancer Res; 1985 Nov; 45(11 Pt 1):5263-9. PubMed ID: 3876881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
